Novo Nordisk volatility elevated into FDA Drugs Advisory Committee Meeting Novo Nordisk November call option implied volatility is at 48, December is at 29, March is at 24; compared to its 26-week average of 26 according to Track Data, suggesting larger near term price movement into a FDA--CDER - Endocrinologic and Metabolic Drugs Advisory Committee Meeting on November 8.
News For NVO From The Last 14 Days
Check below for free stories on NVO the last two weeks.
Subscribe for More Information